FOLFOXIRI for Neoadjuvant Treatment of High-risk Locally Advanced Colorectal Cancer
- Sponsor
- West China Hospital
- Study ID
- NCT05018182
- Phase
- PHASE2
- Status
- Unknown
Conditions
- FOLFOXIRI Regimen
- High-risk Locally Advanced Colorectal Cancer
- Neoadjuvant Chemotherapy
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 70 Years
- Healthy Volunteers
- Not accepted
Interventions
- Oxaliplatin — DRUGOxaliplatin 85 mg/m² Q2w(2 h) before surgery rection and 130 mg/m² Q3w (2 h) after surgery
- Irinotecan — DRUGIrinotecan 150 mg/m² ivgtt(1.5 h) Q2w before surgery rection
- Folinic Acid — DRUGFolinic acid 400 mg/m² ivgtt(2 h) Q2w before surgery rection
- 5FU — DRUG5-FU 2800 mg/m² civ(46 h) Q2w before surgery rection
- Capecitabine — DRUGCapecitabine 1000mg/m² d1-14 po Q3w after surgery rection
Study Details
The main cause of recurrence after surgical treatment of colorectal cancer is distant metastasis. Neoadjuvant chemotherapy has potential benefits of improving the effectiveness of chemotherapy. Preoperative chemotherapy may eradicate microscopic metastatic cancer cells earlier than adjuvant chemotherapy, reduce cancer cell spillage during surgery, and lessen the invasiveness of surgical resection. The FOLFOXIRI regimen has been shown to have a high objective efficiency in advanced colorectal cancer. This phase II trial is to explore the pathological remission rate and safety of stage II/III locally advanced colon cancer with high risk of recurrence to FOLFOXIRI regimen of neoadjuvant chemotherapy alone.
Key Dates
- Start date
- Aug 2, 2021
- Status verified
- Aug 2021
- Primary completion
- Apr 30, 2022
- Completion
- Aug 2, 2022
Study Design
- Enrollment
- 69 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Neoadjuvant chemotherapy4 cycles of neoadjuvant chemotherapy with FOLFOXIRI + operation + 5 cycles of adjuvant chemotherapy with XELOX
Primary Outcome Measure
Pathological response [ Time Frame: up to 24 weeks ]
Central Contacts
- Meng Qiu, Ph.D+8602885423203
- Weibing Leng, Ph.D+8602885423203
Related Studies
- Neoadjuvant Therapy and Contrast-enhanced Mammography for Early Stage Breast CancerEARLY_PHASE1 · Recruiting · Alison Stopeck · Stony Brook, New York
- The Better, Harder, Faster, Stronger StudyRecruiting · Wake Forest University Health Sciences · Winston-Salem, North Carolina